Development of Regenerative Medicine Partnering in Global Industry : Trends and Application 2017
Researchmoz added Most up-to-date research on "Global Regenerative Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts" to its huge collection of research reports.
The Global Regenerative Medicine Partnering 2010-2015: Deal trends, players, financials and
forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in regenerative medicine
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
Track future trends and emerging companies in regenerative medicine- *new feature*
The report takes readers through the regenerative medicine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering regenerative medicine partnering deals.
The report presents average financial deal terms values for regenerative medicine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=301547
The middle section of the report explores the leaders in the regenerative medicine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
One of the key highlights of the report is that over 700 online deals records of actual regenerative medicine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of the report provide an orientation of regenerative medicine dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in regenerative medicine deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.
A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the regenerative medicine field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
The Global Regenerative Medicine Partnering 2010-2015: Deal trends, players, financials and
forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in regenerative medicine
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
Track future trends and emerging companies in regenerative medicine- *new feature*
The report takes readers through the regenerative medicine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering regenerative medicine partnering deals.
The report presents average financial deal terms values for regenerative medicine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=301547
The middle section of the report explores the leaders in the regenerative medicine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
One of the key highlights of the report is that over 700 online deals records of actual regenerative medicine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of the report provide an orientation of regenerative medicine dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in regenerative medicine deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.
A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the regenerative medicine field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
Comments
Post a Comment